Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Apoptotic cell death is a key feature of neurodegenerative diseases like Alzheimer's and Huntington's, and cerebral ischemia.
• Caspase activation plays a critical role in programmed cell death pathways.

Purpose of the Study:

• To investigate the role of caspase activation in ischemic brain injury.
• To evaluate the neuroprotective potential of caspase inhibition in a murine model.

Main Methods:

• Utilized a murine model of middle cerebral artery occlusion (MCAO) to induce ischemic brain injury.
• Measured caspase activation using zDEVD-amino-4-trifluoromethyl coumarin (zDEVD-afc) cleavage assay.
• Assessed caspase-3p20 levels via immunoblotting.
• Administered the caspase inhibitor N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethyl-ketone (zDEVD-fmk) pre- and post-ischemia.

Main Results:

• Caspase activation, indicated by increased zDEVD-afc cleavage and caspase-3p20, was observed 9 hours post-MCAO.
• zDEVD-fmk treatment significantly reduced ischemic damage when administered up to 9 hours after reperfusion.
• Neuroprotection conferred by zDEVD-fmk was long-lasting, persisting for 21 days.

Conclusions:

• The period preceding caspase activation represents a therapeutic window for neuroprotection following mild ischemic brain injury.
• Caspase inhibition demonstrates potential as a neuroprotective strategy for both acute ischemic events and chronic neurodegenerative disorders.
• The extended treatment window and prolonged protection highlight the therapeutic relevance of targeting caspases.